Columbia Laboratories Extends Agreement with Merck Serono for CRINONE Ex-U.S. into 2020

  Columbia Laboratories Extends Agreement with Merck Serono for CRINONE
  Ex-U.S. into 2020

Business Wire

LIVINGSTON, N.J. -- April 9, 2013

Columbia Laboratories, Inc. (Nasdaq: CBRX) has amended its license and supply
agreement with Merck Serono, a division of Merck KGaA (XETRA: MRK.DE),
Darmstadt, Germany, for CRINONE^® (progesterone gel) through May 2020,
representing an extension of five years beyond the current term, which was due
to expire in May 2015. CRINONE is currently approved in over 60 countries,
including a number of emerging markets such as China, where it was approved at
the end of 2008. Merck Serono has marketing rights worldwide except the United
States, where CRINONE is marketed by Actavis, Inc. (NYSE:ACT).

“We are pleased to continue our long-standing partnership with Merck Serono
for CRINONE,” said Frank Condella, Columbia's president and chief executive
officer. “The early renewal of this agreement through 2020 provides long-term
stability for Columbia and surety of supply for Merck Serono as they look to
continue their investment in CRINONE globally. We look forward to continued
positive cash flow from our core business as Merck Serono builds further sales
momentum for CRINONE.”

Under the terms of the amended license and supply agreement, Columbia will
remain the sole supplier of CRINONE to Merck Serono and will continue to sell
CRINONE to Merck Serono on a country by country basis. From 2014 through 2020,
the sourcing conditions for Merck Serono will include incremental volume
discounts to incentivize Merck Serono to continue developing existing markets
and investing in entry into new markets.

About Columbia Laboratories

Columbia Laboratories, Inc. is a publicly traded specialty pharmaceutical
company with a successful history of developing proprietary, vaginally
administered products for women’s health indications. The Company receives
sales and royalty revenues from CRINONE^® (progesterone gel), which is
marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in
over 60 foreign countries.

Columbia's press releases and other company information are available online
at www.columbialabs.com.

The use of the name “Merck” and “Merck Serono” in this press release refers to
Merck KGaA of Darmstadt, Germany. In North America, Merck KGaA operates under
the umbrella brand EMD.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This communication contains forward-looking statements, which statements
are indicated by the words “may,” “will,” “plans,” “believes,” “expects,”
“anticipates,” “potential,” “should,” and similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results to differ materially from those
projected in the forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date on which they are made. Factors that might cause future results to
differ include, but are not limited to, the following: Actavis' and Merck
Serono's success in marketing CRINONE for use in infertility in their
respective markets; successful development by Actavis of a next-generation
vaginal progesterone product for the U.S. market; difficulties or delays in
manufacturing; the availability and pricing of third-party sourced products
and materials; successful compliance with FDA and other governmental
regulations applicable to manufacturing facilities, products and/or
businesses; changes in the laws and regulations; the ability to obtain and
enforce patents and other intellectual property rights; the impact of patent
expiration; the impact of competitive products and pricing; the cost of
evaluating potential strategic transactions; the cost of the Company's pending
relocation to Boston; Columbia’s ability to timely regain compliance with the
Nasdaq minimum closing bid price rule; the strength of the United States
dollar relative to international currencies, particularly the euro;
competitive economic and regulatory factors in the pharmaceutical and
healthcare industry; general economic conditions; and other risks and
uncertainties that may be detailed, from time-to-time, in Columbia's reports
filed with the SEC, including, but not limited to, its Quarterly Report on
Form 10-K for the period ended December 31, 2012. Columbia does not undertake
any responsibility to revise or update any forward-looking statements
contained herein, except as expressly required by law.

CRINONE^® is a registered trademark of Actavis, Inc. in the U.S.

Contact:

Columbia Laboratories, Inc.
Jonathan Lloyd Jones, 973-486-8818
Vice President & CFO
or
The Trout Group LLC
Seth Lewis, 646-378-2952
Senior Vice President